Development of an enzyme immunoassay for detection of antibodies against *Coccidioides* in dogs and other mammalian species

Nancy A. Chow¹, Mark D. Lindsley¹, Orion Z. McCotter¹, Dave Kangiser², Ron D. Wohrle², Wayne R. Clifford², Hayley D. Yaglom³, Laura E. Adams³, Kenneth Komatsu³, Michelle M. Durkin⁴, Rocky J. Baker⁵, Lisa F. Shubitz⁵, Gordana Derado⁷, Tom M. Chiller¹, Anastasia P. Litvintseva *¹

¹ Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, ² Zoonotic Disease Program, Office of Environmental Public Health Sciences, Washington State Department of Health, Olympia, Washington, United States of America, ³ Arizona Department of Health Services, Phoenix, Arizona, United States of America, ⁴ MiraVista Diagnostics, Indianapolis, Indiana, United States of America, ⁵ Oregon Veterinary Diagnostic Laboratory, Oregon State University, Corvallis, Oregon, United States of America, ⁶ Valley Fever Center for Excellence, University of Arizona, Tucson, Arizona, United States of America, ⁷ Biostatistics and Information Management Office, Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

* Current address: Field Services Branch, Division of State and Local Readiness, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Abstract

*Coccidioides* is a soil-dwelling fungus that causes coccidioidomycosis, a disease also known as Valley fever, which affects humans and a variety of animal species. Recent findings of *Coccidioides* in new, unexpected areas of the United States have demonstrated the need for a better understanding of its geographic distribution. Large serological studies on animals could provide important information on the geographic distribution of this pathogen. To facilitate such studies, we used protein A/G, a recombinant protein that binds IgG antibodies from a variety of mammalian species, to develop an enzyme immunoassay (EIA) that detects IgG antibodies against *Coccidioides* in a highly sensitive and high-throughput manner. We showed the potential of this assay to be adapted to multiple animal species by testing a collection of serum and/or plasma samples from dogs, mice, and humans with or without confirmed coccidioidomycosis. We then evaluated the performance of the assay in dogs, using sera from dogs residing in a highly endemic area, and found seropositivity rates significantly higher than those in dogs of non-endemic areas. We further evaluated the specificity of the assay in dogs infected with other fungal pathogens known to cross-react with *Coccidioides*. Finally, we used the assay to perform a cross-sectional serosurvey investigating dogs from Washington, a state in which infection with *Coccidioides* has recently been documented. In summary, we have developed a *Coccidioides* EIA for the detection of antibodies in canines that is more sensitive and has higher throughput than currently available methods, and by testing this assay in mice and humans, we have shown a proof of principle of its adaptability for other animal species.
Introduction

Coccidioidomycosis, also known as Valley fever, is a fungal disease caused by the soil-dwelling fungi *Coccidioides immitis* or *C. posadasii*. The disease has been characterized as endemic to the arid regions of southwestern United States, Mexico, Central America, and South America [1, 2]. Humans and a variety of mammalian species, including dogs, cats, horses, South American camels, and marine mammals [3–7], can be infected when aerosolized arthroconidia (asexual spores) are inhaled. Although the precise ecological niche of *Coccidioides* remains unknown, it is widely accepted that the fungus grows in soil as hyphae and produces infective arthroconidia that become airborne upon soil disturbance [8–10].

Much of the work that mapped *Coccidioides* to the southwestern United States was derived from skin testing studies, which test for the presence of a delayed-type hypersensitivity response to *Coccidioides* indicating previous exposure. These studies were conducted in the 1940-50s on people who had no or limited reported travel outside of known endemic areas [11–14]. In addition, skin testing studies were performed on cattle as a sentinel species for human cases [15]. This approach was based on the assumption that animals travel considerably less than humans, and that exposure rates of a given area will reflect the presence of *Coccidioides* in that geographic area.

More recently, studies have used the gold-standard assay for antibody detection, agar gel immunodiffusion (AGID), to investigate dogs as a sentinel species for human cases [16]. Both prevalence and incidence of *Coccidioides* exposure in dogs were assessed in southern Arizona, an area known to be highly endemic for coccidioidomycosis [16]. In addition, dogs have been used in California and Texas to model the spatial distribution of *Coccidioides* and identify areas of high risk exposure for humans [17, 18].

Notably, recent findings demonstrating the presence of *Coccidioides* in the Pacific Northwest, specifically south central Washington, have challenged our current understanding of where this fungus resides and have highlighted the need to generate more accurate distribution maps [19–21]. Although surveillance methods that involve skin testing or serological assays that detect *Coccidioides* exposure in humans are available [11, 22, 23], it is becoming increasingly difficult to find people with limited travel history between known and unknown endemic areas. Testing animals susceptible to coccidioidomycosis may help to better understand the geographic distribution of this disease; however, few assays are available for testing animals. To date, there is no assay for detecting *Coccidioides* antibodies that is high-throughput, highly sensitive, and adaptable to a variety of animal species.

AGID is a highly specific test that can detect both IgM and IgG antibodies against *Coccidioides* in a variety of host species [22]; however, this method is time-consuming and is not suitable for large-scale surveillance studies. Conversely, EIAs are more sensitive, have a higher throughput, and can generate results in less than two hours compared to AGID, which requires 24–48 hours for incubation [24]. However, the main limitation of existing *Coccidioides* EIAs is that most of them are limited to detection in humans. The only reported study that used EIA for detection of anti-*Coccidioides* antibodies in animals other than humans is a report by Catalán-Dibene et al., who developed and field tested an EIA for testing rodents, using a mouse-specific secondary antibody. In addition, Durkin et al. developed a *Coccidioides* antigen EIA that can be applied to multiple host species [25], but a later investigation using this assay in dogs found antigen detection to be an insensitive method as compared to antibody detection [26].

In this study, we report the use of conjugated fusion protein A/G to develop an EIA that can detect antibodies against *Coccidioides* in a variety of animal species that are susceptible to coccidioidomycosis. Protein A/G is a recombinant protein capable of binding IgG antibodies
from many animal species including dogs, cats, mice, rats, horses, alpacas, and rabbits. Previous studies have shown its multi-species use in immunoassays for detection of *Toxoplasma gondii* and *Borrelia* spp. [27–29]. For this assay, we demonstrated adaptability to dogs by testing serum samples from dogs with coccidioidomycosis and other endemic fungal infections, as well as from dogs residing in known endemic and non-endemic areas. We also performed a cross-sectional serosurvey investigating dogs in Washington, an area where burden of disease remains unclear and prevalence of *Coccidioides* exposure in dogs or any other animal species has not been investigated.

**Materials and methods**

**Human and animal sera**

All sera and/or plasma for the development and evaluation of this assay were residual specimens acquired from existing collections. No animal or human specimens were collected specifically for this project. All sera was shipped to the Centers for Disease Control and Prevention (CDC) frozen and stored for varying times at room temperature (RT), 4˚C, and -80˚C.

**Sera for assay development.** Canine sera positive for coccidioidomycosis (n = 37), blastomycosis (n = 10), and histoplasmosis (n = 10) were residual sera from anonymous specimens received after routine reference clinical testing at MiraVista Diagnostics Laboratory (Indianapolis, IN, USA). Residual murine plasma from C57BL/6 mice vaccinated with the attenuated *Coccidioides* and the uninfected controls were acquired from an unrelated study by the University of Arizona. Negative control sera from mice and healthy dogs residing in non-endemic areas were purchased from BioreclamationIVT (Chesterstown, MD, USA). Human sera were from known *Coccidioides* seropositive and seronegative specimens from CDC collected under CDC IRB protocol exemption #4013, and consisted of anonymized sera collected as part of CDC public health surveillance efforts.

**Sera for assay evaluation.** To evaluate assay performance, we used sera from dogs that resided in known endemic regions of southern Arizona, sera from dogs that resided in non-endemic regions (S1 Table), and sera from dogs who resided in the newly identified endemic region Washington. Remnant dog sera from Arizona (n = 212) were received from a previous study by the Rickettsial Zoonosis Branch, CDC, which were obtained in three counties (Cochise, Santa Cruz, and Yuma) located near the U.S.-Mexico border. Serum was collected by rabies clinics, animal control centers, and animal humane societies. Information collected on the dogs included, age group (<1, 1–5, 6+ years), size (small, <20; medium, 20–55; large, 56+ pounds), county of residence (Cochise, Yuma, Santa Cruz), and ownership status (stray/free-roaming or owned/relinquished by the owner).

Samples from non-endemic areas (n = 663) were donated by two centers, Kansas State University (KSU) Veterinary Diagnostic Laboratory (Manhattan, KS, USA) and North Carolina State University (NCSU) College of Veterinary Medicine (Raleigh, NC, USA), and represented 36 states (S1 Table), all thought to be non-endemic for coccidioidomycosis. Serum was submitted by local providers for rabies (KSU) or tick-borne diseases (NCSU) diagnostic testing and surveillance and found to be seronegative for both. For both studies, history of travel to endemic areas for *Coccidioides* was not collected.

From Washington, remnant serum from dogs (n = 1041) obtained during routine veterinary examination was received from 18 veterinary clinics across the state with 88.8% (924/1041) of samples collected from the eastern arid regions of Washington. Clinics were asked to provide available residual serum samples and a residential zip code associated with the dog.
Samples were collected during both routine healthy check-ups and during examinations for a variety of medical conditions.

**Protein A/G *Coccidioides* antibody EIA**

The new protein A/G *Coccidioides* antibody EIA for the detection of IgG antibodies employed the use of the antigen coated plates from the OMEGA *Coccidioides* Antibody Enzyme Immunoassay (IMMY; Norman, OK, USA). This product was chosen over other commercially available products because the kit provides two separate plates for detection of IgG antibody (CF antigen-coated plate) and IgM antibody (TP antigen-coated plate) as compared to other kits that combine CF and TP antigen into one plate for simultaneous detection of IgG and IgM antibodies. The sensitivity of the assay should be improved using antigen coated plates that detects predominately IgG, as protein A/G does not bind to IgM.

**Assay procedure.** The manufacturer’s assay procedure was followed with the following exceptions: only the CF antigen-coated 96-well plate was used for antibody detection and EIA kit conjugate was substituted with a recombinant peroxidase conjugated protein A/G (Thermo Fisher Scientific, Rockford, IL, USA) for antibody detection. To perform the assay, 100 μl of the kit positive control, calibrator control, and animal serum diluted with the kit specimen diluent was added to the respective microwells of the CF antigen-coated plate. After a 30-min incubation at RT, microwells underwent three washes with the kit’s wash buffer using an ELx50 Microplate Strip Washer (BioTek, Winooski, VT, USA). After three washes, excess wash buffer was removed by striking the plate multiple times on paper towels. Protein A/G was diluted with the kit specimen diluent, and added to the microwells and left to incubate for 30 min. Three washes were performed again followed by striking the plate multiple times on paper towels, and 100 μl of the kit TMB substrate was then added to the microwells. After a 10-min incubation, 100 μl of the kit stop solution was added to each microwell and the optical density of each well was read at 450 nm with Molecular Devices SpectraMax 250 Microplate Reader (GMI, Ramsey, MN, USA). EIA units were calculated by normalizing the OD value of each sample by the OD value of the kit calibrator control. Thus, a sample with an EIA unit equal to 1.00 had an OD value equal to that of the calibrator.

**Determination of optimal dilutions for protein A/G and sera.** To determine the optimal concentration of the conjugated protein A/G for use in the EIA, serial 2-fold dilutions of protein A/G (1:10,000 to 1:80,000) were assayed against serially diluted *Coccidioides* or *Histoplasma* reagent control anti-sera developed for the use in AGID. At all protein A/G dilutions between 1:10,000 and 1:80,000, the results of the EIA assay were able to distinguish *Coccidioides* from *Histoplasma* when the AGID control anti-sera was diluted at 1:100 (S2 Table). The largest difference in EIA units was observed when using protein A/G at a dilution of 1:10,000; therefore, we chose this dilution for the remainder of the study. Next, we found the optimal serum dilution for this assay in dogs and mice to be 1:25 (S3 Table).

**Agar Gel Immunodiffusion (AGID)**

AGIDs for detection of IgG antibodies against *Coccidioides* immunodiffusion complement fixation (IDCF) antigen was performed according to IMMY’s protocol using the *Coccidioides* Immunodiffusion reagents from IMMY. Specifically, *Coccidioides* IDCF Antigen (IMMY) and *Coccidioides* IDCF Positive Control (IMMY) were plated on precast Cleargel agar plates (IMMY). Plates were incubated in a humidified chamber at RT, and results were assessed in 72 hours.
Data analysis

ROC curve analysis (performed using SigmaPlot 11.2, Sysat Software, Inc., San Jose, CA, USA) was used to determine the cutoff for the protein A/G EIA assay. Fisher exact chi-square test was used to compare proportions of dogs positive for IgG antibodies against *Coccidioides* from Arizona, Washington, and non-endemic areas. Simple logistic regression was used to compare the odds of testing positive for Cocci between geographic regions. Two sample t-test was used to compare mean EIA values between infected and healthy dog and mouse samples. Wilcoxon rank-sum test was used to compare median EIA values for human isolates, due to small sample size for human data. Exact McNemar’s test was used to compare the difference in dependent proportions from EIA and AGID tests. Univariable and multivariable logistic regression analyses were used to investigate the risk factors related to seropositivity. Statistical analyses were conducted using (SAS v. 9.4, SAS Institute, Cary, NC, USA). All p-values correspond to 2-sided tests, unless otherwise stated, and p-values of 0.05 or less were considered to indicate statistical significance.

Results

Use of protein A/G allows for detection of IgG antibodies against *Coccidioides* in multiple species

We first assessed whether the protein A/G *Coccidioides* antibody EIA was able to detect IgG antibodies against *Coccidioides* from multiple mammalian species. Fig 1 demonstrates the assay’s ability to distinguish between healthy and *Coccidioides*-infected mice (p < 0.01), dogs (p < 0.001), and humans (p = 0.057).

Development of the protein A/G EIA for *Coccidioides* using sera from naturally infected dogs

The cutoff value of the protein A/G *Coccidioides* antibody EIA was determined by Receiver Operating Characteristic (ROC) curve analysis, a method that graphs sensitivity (true positive frequency) versus 1–specificity (false positive frequency) across varying cutoffs in the unit square. Serum obtained from healthy dogs residing in non-endemic areas (n = 25) and from

![Fig 1. Detection of IgG antibodies against *Coccidioides* from multiple mammalian species using protein A/G. EIA units from healthy and *Coccidioides*-infected mouse, dog, and human sera/plasma samples. The y-axis is split with a scale of 0–1.5 EIA units and of 1.5–20 EIA units.](https://doi.org/10.1371/journal.pone.0175081.g001)
dogs with a confirmed diagnosis of coccidioidomycosis (n = 37) was analyzed. The estimated area under the ROC curve was found to be 0.97 (95% confidence interval (CI) = [0.93, 1.01], standard error = 0.02, p<0.001), indicating a high degree of diagnostic accuracy for the protein A/G Coccidioides antibody EIA (Fig 2). The cutoff value of 1.33 EIA units yielded a high degree of sensitivity and specificity for the assay and thus was used as the cutoff for the rest of our analysis.

At this cutoff value, 24 of 25 serum samples from healthy dogs tested negative for IgG antibodies against Coccidioides, for a specificity of 96.0% (95% CI = [86.3, 100], Table 1). Of the serum samples from dogs diagnosed with coccidioidomycosis, 35 of 37 tested positive for a sensitivity of 94.6% (95% CI = [81.8, 99.3], Table 1). Samples were also analyzed by AGID and compared to the protein A/G EIA (Table 2); agreement between the two assays was found to be 90.0% (56/62). By AGID, 30 of 37 serum samples from dogs diagnosed with coccidioidomycosis

**Fig 2.** ROC curve analysis shows a high degree of diagnostic accuracy for the assay. Sensitivity and 1-Specificity were plotted for healthy dogs (n = 25) and dogs confirmed with coccidioidomycosis (n = 37). Estimated area under the curve (A) is 0.97.

https://doi.org/10.1371/journal.pone.0175081.g002
tested positive for a sensitivity of 81.1% (95% CI = [64.8, 92.0]). All 25 serum samples from healthy dogs tested negative by AGID for a specificity of 100% (95% CI = [86.3, 100]). Comparing the EIA and AGID assays by an exact McNemar’s test resulted in a p-value of 0.014, thereby concluding that the tests are significantly different.

To assess cross-reactivity of antibodies against other endemic fungal pathogens, we tested serum samples from dogs clinically diagnosed with two other diseases caused by dimorphic fungi (Table 3), histoplasmosis (n = 10) and blastomycosis (n = 10). For serum samples from dogs with confirmed histoplasmosis, 9 (90.0%) tested negative for IgG antibodies against *Coccidioides*. For serum samples from dogs with confirmed blastomycosis, all 10 tested negative.

Use of the protein A/G EIA for veterinary testing of known and newly identified endemic regions

Using the protein A/G EIA, we estimated the prevalence of anti-*Coccidioides* antibodies among dogs from two states, one with a known level of endemnicity (Arizona) and another with an unknown level (Washington), as well as dogs from non-endemic areas. Of dogs residing in Arizona, 43/212 (20.3%) tested positive for IgG antibodies against *Coccidioides* (Table 4). In contrast, 30/663 (4.5%) of control dogs from non-endemic regions tested positive (Table 4). Arizona dogs had a significantly higher odds of testing positive compared to dogs from non-endemic areas (OR = 5.37, 95% CI = [3.27, 8.82], p-value < 0.001, Table 4). The proportion of Arizona dogs that had antibodies against *Coccidioides* was higher among free-roaming or stray dogs (24/68; 30.8%) than those that were owned or relinquished by the owner (19/111; 14.6%).

Dogs that were free-roaming or stray had increased odds of testing positive compared to dogs who were owned or relinquished by their owner (OR = 2.59, 95% CI = [1.19, 5.66], p-value < 0.001), (Table 5). On univariable analysis, the other potential risk factors examined: age group, size, and county of residence were not significantly associated with seropositivity in dogs (Table 5). Furthermore, there were no significant interactions between ownership status and these other characteristics. On multivariable logistic regression analysis, after adjusting for age, OR for positivity increases to 2.86 (95% CI = [1.38, 5.93], p-value < 0.001).

To determine seropositive rates of dogs in Washington, serum from dogs (n = 1041) collected from 18 veterinary clinics within the state of Washington were tested and 30/1041 (2.9%) tested positive for antibodies to *Coccidioides* (Table 4). While dogs tested in Arizona have significantly higher odds of being positive, compared to non-endemic states, dogs tested in Washington did not have a significantly higher odds of testing positive for antibodies to *Coccidioides* compared to dogs from non-endemic areas (OR = 0.63, 95% CI = [0.37, 1.05], Table 4).

**Discussion**

Identifying areas of geographic risk for acquiring an infection with *Coccidioides* is essential for healthcare providers and public health professionals to promptly identify persons with Valley
Table 2. Comparison of AGID and EIA results for dog sera from confirmed coccidioidomycosis cases and healthy controls.

| Cases (n = 37) | AGID result | EIA result | EIA units |
|---------------|-------------|------------|-----------|
| 1             | +           | +          | 19.84     |
| 2             | +           | +          | 16.77     |
| 3             | +           | +          | 16.44     |
| 4             | +           | +          | 16.40     |
| 5             | +           | +          | 15.34     |
| 6             | +           | +          | 14.85     |
| 7             | +           | +          | 14.20     |
| 8             | +           | +          | 13.72     |
| 9             | +           | +          | 13.55     |
| 10            | -           | +          | 12.76     |
| 11            | +           | +          | 12.71     |
| 12            | +           | +          | 12.11     |
| 13            | +           | +          | 10.56     |
| 14            | +           | +          | 10.49     |
| 15            | +           | +          | 9.85      |
| 16            | +           | +          | 9.31      |
| 17            | +           | +          | 9.02      |
| 18            | +           | +          | 7.18      |
| 19            | +           | +          | 6.75      |
| 20            | +           | +          | 5.30      |
| 21            | +           | +          | 4.89      |
| 22            | +           | +          | 3.95      |
| 23            | +           | +          | 3.68      |
| 24            | +           | +          | 3.21      |
| 25            | -           | +          | 3.17      |
| 26            | +           | +          | 2.90      |
| 27            | +           | +          | 2.84      |
| 28            | +           | +          | 2.82      |
| 29            | -           | +          | 2.77      |
| 30            | -           | +          | 2.68      |
| 31            | +           | +          | 2.68      |
| 32            | +           | +          | 2.12      |
| 33            | +           | +          | 1.91      |
| 34            | -           | +          | 1.79      |
| 35            | +           | +          | 1.34      |
| 36            | -           | -          | 0.65      |
| 37            | -           | -          | 0.38      |

Controls (n = 25) | AGID result | EIA result | EIA units |
|-----------------|-------------|------------|-----------|
| 1               | -           | +          | 1.33      |
| 2               | -           | -          | 1.23      |
| 3               | -           | -          | 1.18      |
| 4               | -           | -          | 0.90      |
| 5               | -           | -          | 0.90      |
| 6               | -           | -          | 0.76      |
| 7               | -           | -          | 0.71      |
| 8               | -           | -          | 0.67      |

(Continued)
fever. However, the available maps of endemic regions were developed in the 1940-50s by performing skin testing on cattle and people who had not left their county of birth and are likely outdated [14]. Replicating such methods in today’s more mobile population would be challenging. Therefore, additional methods, such as targeted environmental sampling and regional veterinary surveillance, are needed to identify the current geographic range of *Coccidioides*.

Table 2. (Continued)

|   |   |   |   |
|---|---|---|---|
| 9 | - | - | 0.67 |
| 10 | - | - | 0.66 |
| 11 | - | - | 0.59 |
| 12 | - | - | 0.58 |
| 13 | - | - | 0.58 |
| 14 | - | - | 0.54 |
| 15 | - | - | 0.51 |
| 16 | - | - | 0.40 |
| 17 | - | - | 0.40 |
| 18 | - | - | 0.40 |
| 19 | - | - | 0.37 |
| 20 | - | - | 0.30 |
| 21 | - | - | 0.29 |
| 22 | - | - | 0.28 |
| 23 | - | - | 0.26 |
| 24 | - | - | 0.17 |
| 25 | - | - | 0.10 |

(+) and (-) represent positive and negative tests results, respectively.

https://doi.org/10.1371/journal.pone.0175081.t002

Table 3. Sensitivity and specificity of EIA in dogs.

|                     | Total | Positive | Negative |
|---------------------|-------|----------|----------|
| Sensitivity         | 37    | 35 (94.6%)| 2 (5.4%) |
| Specificity         | 25    | 1 (4%)   | 24 (96%) |
| Cross-Reactivity with *Histoplasma* | 10    | 1 (10%) | 9 (90%) |
| Cross-Reactivity with *Blastomyces* | 10    | 0 (0%) | 10 (100%) |

Positive and negative rates were assessed for healthy dogs (n = 25), dogs with confirmed coccidioidomycosis (n = 37), blastomycosis (n = 10), and histoplasmosis (n = 10).

https://doi.org/10.1371/journal.pone.0175081.t003

Table 4. Comparison of EIA reactivity in sera from dogs residing in endemic (Arizona), non-endemic, and newly endemic (Washington) areas.

|                     | Positive | Negative | OR^a^ (95% CI^b^) |
|---------------------|----------|----------|------------------|
| Arizona (n = 212)   | 43 (20.3%)| 169 (79.7%)| 5.37 (3.27, 8.82) |
| Washington (n = 1041)| 30 (2.9%)| 1011 (97.1%)| 0.63 (0.37, 1.05) |
| Non-endemic states (n = 663) | 30 (4.5%)| 633 (95.5%)| Ref^c^ |

^a^ Odds ratio  
^b^ Confidence Interval  
^c^ Reference

https://doi.org/10.1371/journal.pone.0175081.t004
In an effort to contribute to updating *Coccidioides* distribution maps, we developed and validated an EIA that is capable of detecting IgG antibodies against *Coccidioides* that is sensitive, high-throughput, and adaptable to testing multiple mammals, including dogs. We demonstrated that a cutoff value of 1.33 EIA units for testing dog sera provided a high degree of sensitivity and specificity that were comparable to the reported rates for the original OMEGA *Coccidioides* Antibody Enzyme Immunoassay (IMMY) [30]. The assay was also highly specific with minimal signal detected from healthy controls, and animals with confirmed *Blastomyces* and *Histoplasma* infections. Specifically, of 20 animals with known *Histoplasma* and *Blastomyces* infections tested with our assay, only one cross-reacted with *Coccidioides*. However, this was not unexpected as cross-reactivity between *Coccidioides*, *Histoplasma*, and *Blastomyces* antigens has been reported previously (32, 33).

Of the control dogs residing in non-endemic areas for *Coccidioides*, 4.5% tested positive. This low level may be a result of cross-reactivity with *Blastomyces* and *Histoplasma*, which are endemic to the areas from which non-endemic sera were obtained. Alternatively, since history of travel for these dogs was unknown, it is possible that some of the seropositive dogs traveled into endemic regions and were exposed to *Coccidioides*. Recording travel history may improve the sensitivity of future surveys.

From our investigation of dogs with antibodies against *Coccidioides* from known endemic areas of the United States, we observed that in the endemic area of southern Arizona, 20.3% of tested dogs possessed antibodies against *Coccidioides*, as compared to 4.5% of dogs from the non-endemic area. In a similar cross-sectional study of southern Arizona dogs (4–18 months old) using AGID for detection, Shubitz et al. found 8% (32/381) of tested dogs to be positive for antibodies against *Coccidioides* [16]. The higher positivity proportion of 20.3% in our study is likely attributed to the greater sensitivity of EIAs compared to AGID. Other studies investigating risk factors associated with *Coccidioides* infection in dogs, identified

### Table 5. Comparison of characteristics between Arizona dogs with positive and negative presence of IgG antibodies.

| Characteristics | Positive N (%) Total n = 43 (100%) | Negative N (%) Total n = 168 (100%) | Unadjusted Odds Ratio (95% CI) |
|-----------------|-------------------------------------|-------------------------------------|-------------------------------|
| **Age (years)** |                                     |                                     |                               |
| <1              | 8 (25.0)                            | 24 (75.0)                           | Ref b                         |
| 1–5             | 28 (18.9)                           | 120 (81.1)                          | 0.70 (0.29–1.72)              |
| ≥6              | 7 (22.6)                            | 24 (77.4)                           | 0.88 (0.27–2.80)              |
| **Ownership Status** |                                   |                                     |                               |
| Owned/Relinquished by Owner | 19 (14.6)                         | 111 (85.4)                          | Ref                           |
| Stray/Free-Roaming      | 24 (30.8)                           | 54 (69.2)                            | 2.59 (1.31–5.15)              |
| **Size** |                                     |                                     |                               |
| Small (<20 pounds) | 10 (15.4)                           | 55 (84.6)                            | Ref                           |
| Medium (20–55 pounds) | 18 (22.8)                           | 61 (77.2)                            | 1.62 (0.69–3.82)              |
| Large (56+ pounds)      | 15 (22.4)                           | 52 (77.6)                            | 1.59 (0.66–3.85)              |
| **County** |                                     |                                     |                               |
| Cochise | 6 (15.4)                           | 33 (84.6)                            | Ref                           |
| Yuma          | 18 (25.7)                           | 52 (74.3)                            | 1.90 (0.69–5.29)              |
| Santa Cruz    | 19 (18.6)                           | 83 (81.4)                            | 1.26 (0.46–3.43)              |

Characteristics of age (years), ownership status, size, and county were assessed in Arizona dogs.

Four observations were omitted from analysis due to missing data.

- **Confidence interval**
- **Reference**
- 3 Dogs were missing Ownership Status

https://doi.org/10.1371/journal.pone.0175081.t005
increased risk in dogs that were kept outside and/or roamed on large areas of land (Butkie-
wicz et al., 2005). Similar to those studies, we found that dogs that were free-roaming or
strays had a higher positive rate than owned or relinquished dogs which also suggests that
more prolonged or intense time spent outdoors may increase Coccidioides exposure. The
agreement between results obtained from different investigations further validate utility of
our test for dog surveillance.

We investigated seropositivity rates of dogs residing in Washington where locally acquired
cases have recently been identified. We found the seropositivity rate to be comparable between
Washington dogs and dogs residing in other, non-endemic areas, thereby concluding that the
degree of Coccidioides exposure in Washington dogs is low. These results showed that although
locally-acquired human cases of coccidioidomycosis have occurred in Washington, the
regional background IgG seropositive rate of this convenience survey was lower than an estab-
lished endemic area. Continued surveillance could help track whether the range of Coccidioides
expands or becomes more prevalent in areas of Washington. Based on our results from the
Arizona population and previous studies, future studies might target stray or free-roaming
dogs in contrast to this serosurvey that predominately tested sera from owned dogs visiting
veterinary clinics.

One limitation of the assay is that it only detects IgG antibodies against Coccidioides in that
protein A/G does not bind to IgM antibodies. Given that IgM antibodies against Coccidioides
are associated with the initial antibody response during early primary infection [22] while IgG
antibodies develop afterwards and persist longer as IgM levels wane, surveillance projects
using the assay developed here would miss early acute Coccidioides infections. However, for
the purpose of our study, the detection of IgG is more informative compared to IgM, as IgG
levels are more likely to correlate with the previous exposure. Similarly, Shubitz et al. looked at
both IgG and IgM antibodies against Coccidioides by AGID in dogs residing in Arizona and
concluded that the shorter window of host IgM production and lower concentration of circu-
lating IgM antibodies make it difficult to detect early Coccidioides infections with serological
assays [16].

Finally, this assay can be used as a tool in investigating and mapping the expansion of the
endemic region for coccidioidomycosis. We have validated the protein A/G EIA for Coccidi-
oides detection in dogs, and demonstrated a proof of principle of its adaptability for other
animal species. In the future, cutoff values for other species will need to be determined so that
this method may be adopted for large serological studies in other mammals whose IgG anti-
bodies are recognized by protein A/G, such as horses, cattle, cats, and others.

Supporting information

S1 Data. Data for Fig 1.
(XLSX)

S2 Data. Data for Fig 2 and Table 1.
(XLSX)

S3 Data. Data for Table 3.
(XLSX)

S4 Data. Data for Table 4.
(XLSX)

S5 Data. Data for Table 5.
(XLSX)
S1 Table. Represented non-endemic states for *Coccidioides*. Number of serum samples received from each non-endemic state (N = 36).

(DOCX)

S2 Table. Determination of the optimal concentration of peroxidase-conjugated protein A/G for use in the EIA assay. Optimal concentration of protein A/G with a serum dilution of 1:100 was found to be 1:10,000. a dilution of Protein A/G; b Sera from rabbit inoculated with *Coccidioides*; c Sera from rabbit inoculated with *Histoplasma*; d EIA units (positive cutoff 1.33); e None Detected.

(DOCX)

S3 Table. Determination of the optimal dilution of dog and mouse sera for use in the EIA assay. EIA results for healthy and *Coccidioides* infected dog (A) and mouse (B) sera at varying dilutions, 1/25 yielded the largest difference in EIA unites between health and *Coccidioides* infected species. a None Detected.

(DOCX)

Acknowledgments

We are very grateful to Ed Breitschwerdt and Barbara Hegarty (Vector Borne Disease Diagnostic Lab, North Carolina State University) and Beth McQuade (Rabies Laboratory, Kansas State University) for the generous donation of sera from non-endemic areas. We thank Cari Wade (Wade Veterinary Services, Inc) for help in providing sera from dogs with confirmed coccidioidomycosis.

We also thank Shawnee Anderson and Li Deng (Division of Foodborne, Waterborne, and Environmental Diseases, CDC) for statistical analysis, and Kaitlin Benedict and Brendan Jackson (Mycotic Diseases Branch, CDC) for manuscript edits. Any use of trade names is for descriptive purposes and does not imply endorsement by the U.S. Government. The finding and conclusions in this article are those of the authors and do not necessarily represent the views of the CDC.

Author Contributions

Conceptualization: NAC MDL RDW TMC APL.

Data curation: NAC DK.

Formal analysis: NAC OZM GD.

Funding acquisition: RDW TMC APL.

Investigation: NAC MDL OZM.

Methodology: NAC MDL APL.

Project administration: NAC MDL APL.

Resources: DK RDW WRC HDY LEA KK RJB MMD LS.

Supervision: TMC APL.

Validation: NAC MDL OZM.

Visualization: NAC MDL OZM.

Writing – original draft: NAC MDL OZM APL.
References

1. Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, et al. Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. Clin Microbiol Rev. 2013; 26(3):505–25. https://doi.org/10.1128/CMR.00005-13 PMID: 23824371

2. Fisher MC, Koenig GL, White TJ, Taylor JW. Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia. 2002; 94(1):73–84. PMID: 12156479

3. Graupmann-Kuzma A, Valentine BA, Shubitz LF, Dial SM, Watrous B, Torququist SJ. Coccidioidomycosis in dogs and cats: a review. J Am Anim Hosp Assoc. 2008; 44(5):226–35. https://doi.org/10.5326/0440226 PMID: 18762558

4. Higgins JC, Leith GS, Voss ED, Pappagianis D. Seroprevalence of antibodies against Coccidioides immitis in healthy horses. J Am Vet Med Assoc. 2005; 226(11):1888–92. PMID: 15934257

5. Huckabone SE, Gulland FM, Johnson SM, Colegrove KM, Dodd EM, Pappagianis D, et al. Coccidioidomycosis and other systemic mycoses of marine mammals stranded along the central California, USA coast: 1998–2012. J Wildl Dis. 2015; 51(2):295–308. https://doi.org/10.7589/2014-06-143 PMID: 25647598

6. Ashburn LL E C. Spontaneous coccidioidal granuloma in the lungs of wild rodents. Archives of Pathology. 1942; 34:791–800.

7. Shubitz LF. Comparative aspects of coccidioidomycosis in animals and humans. Ann N Y Acad Sci. 2007; 1111:395–403. https://doi.org/10.1196/annals.1406.007 PMID: 17332082

8. Huppert M, Sun SH, Harrison JL. Morphogenesis throughout saprobic and parasitic cycles of Coccidioides immitis. Mycopathologia. 1982; 78(2):107–22. PMID: 7099241

9. Maddy KT. Observations on Coccidioides Immitis Found Growing Naturally in Soil. Ariz Med. 1965; 22:281–8. PMID: 14262164

10. Sun SH, Sekhon SS, Huppert M. Electron microscopic studies of saprobic and parasitic forms of Coccidioides immitis. Sabouraudia. 1979; 17(3):265–73. PMID: 531717

11. Wack EE, Ampel NM, Sunenshine RH, Galgiani JN. The Return of Delayed-Type Hypersensitivity Skin Testing for Coccidioidomycosis. Clin Infect Dis. 2015; 61(5):787–91. https://doi.org/10.1093/cid/civ388 PMID: 25979308

12. Cowper HH, Emmett J. Coccidioidomycosis in San Fernando Valley; report of a study carried out in 1951–1952. Calif Med. 1953; 79(2):97–8. PMID: 13067021

13. Doto IL, Tosh FE, Farnsworth SF, Furcolow ML. Coccidioidin, histoplasmin, and tuberculin sensitivity among school children in Maricopa County, Arizona. Am J Epidemiol. 1972; 95(5):464–74. PMID: 5021934

14. Edwards PQ, Palmer CE. Prevalence of sensitivity to coccidioidin, with special reference to specific and nonspecific reactions to coccidioidin and to histoplasmin. Dis Chest. 1957; 31(1):35–60. PMID: 13384171

15. Maddy KT, Crecelius HG, Cornell RG. Distribution of Coccidiodes immitis determined by testing cattle. Public Health Rep. 1960; 75:955–62. PMID: 13765054

16. Shubitz LE, Butkiewicz CD, Dial SM, Lindan CP. Incidence of coccidioides infection among dogs residing in a region in which the organism is endemic. J Am Vet Med Assoc. 2005; 226(11):1846–50. PMID: 15938056

17. Gautam R, Srinath I, Clavijo A, Szonyi B, Bani-Yaghoub M, Park S, et al. Identifying areas of high risk of human exposure to coccidioidomycosis in Texas using serology data from dogs. Zoonoses Public Health. 2013; 60(2):174–81. https://doi.org/10.1111/j.1863-2378.2012.01526.x PMID: 22856539

18. Grayzel SE, Martinez-Lopez B, Sykes JE. Risk Factors and Spatial Distribution of Canine Coccidioidomycosis in California, 2005–2013. Transbound Emerg Dis. 2016.

19. Benedict K, Thompson GR 3rd, Deresinski S, Chiller T. Mycotic Infections Acquired outside Areas of Known Endemicity, United States. Emerg Infect Dis. 2015; 21(11):1935–41. https://doi.org/10.3201/eid2111.141950 PMID: 26485441

20. Litvintseva AP, Marsden-Haug N, Hurst S, Hill H, Gade L, Driebe EM, et al. Valley fever: finding new places for an old disease: Coccidioides immitis found in Washington State soil associated with recent human infection. Clin Infect Dis. 2015; 60(1):e1–3. https://doi.org/10.1093/cid/ciu681 PMID: 25165087

21. Marsden-Haug N, Goldoft M, Raslton C, Limaye AP, Chua J, Hill H, et al. Coccidioidomycosis acquired in Washington State. Clin Infect Dis. 2013; 56(6):847–50. https://doi.org/10.1093/cid/cis1028 PMID: 23223598
22. Pappagianis D. Serologic studies in coccidioidomycosis. Semin Respir Infect. 2001; 16(4):242–50. PMID: 11740825
23. Pappagianis D, Zimmer BL. Serology of coccidioidomycosis. Clin Microbiol Rev. 1990; 3(3):247–68. PMID: 2200605
24. Kaufman L, Sekhon AS, Moledina N, Jalbert M, Pappagianis D. Comparative evaluation of commercial Premier EIA and microimmunodiffusion and complement fixation tests for Coccidioides immitis antibodies. J Clin Microbiol. 1995; 33(3):618–9. PMID: 7751365
25. Durkin M, Connolly P, Kuberski T, Myers R, Kubak BM, Bruckner D, et al. Diagnosis of coccidioidomycosis with use of the Coccidioides antigen enzyme immunoassay. Clin Infect Dis. 2008; 47(8):e69–73. https://doi.org/10.1086/592073 PMID: 18781884
26. Kirsch EJ, Greene RT, Prahl A, Rubin SI, Sykes JE, Durkin MM, et al. Evaluation of Coccidioides antigen detection in dogs with coccidioidomycosis. Clin Vaccine Immunol. 2012; 19(3):343–5. https://doi.org/10.1128/CVI.05631-11 PMID: 22278324
27. Bhide MR, Curlik J, Travnicke M, Lazar P. Protein A/G dependent ELISA a promising diagnostic tool in Lyme disease seroprevalence in game animals and hunting dogs. Comp Immunol Microbiol Infect Dis. 2004; 27(3):191–9. https://doi.org/10.1016/j.cimid.2003.10.001 PMID: 15001314
28. Zhang D, Wang Z, Fang R, Nie H, Feng H, Zhou Y, et al. Use of protein AG in an enzyme-linked immunoassay for serodiagnosis of Toxoplasma gondii infection in four species of animals. Clin Vaccine Immunol. 2010; 17(3):485–6. https://doi.org/10.1128/CVI.00479-09 PMID: 20071493
29. Eliasson M, Olsson A, Palmcrantz E, Wiberg K, Inganas M, Guss B, et al. Chimeric IgG-binding receptors engineered from staphylococcal protein A and streptococcal protein G. J Biol Chem. 1988; 263(9):4323–7. PMID: 2964447
30. Lindsley MD, Ahn Y, Mc Cotter O, Gade L, Hurst SF, Brandt ME, et al. Evaluation of the Specificity of Two Enzyme Immunoassays for Coccidioidomycosis by Using Sera from a Region of Endemicity and a Region of Nonendemicity. Clin Vaccine Immunol. 2015; 22(10):1090–5. https://doi.org/10.1128/CVI.00375-15 PMID: 26245352